Analysts Issue Forecasts for Chemed Co.’s Q1 2024 Earnings (NYSE:CHE)

Chemed Co. (NYSE:CHEGet Rating) – Equities research analysts at Oppenheimer issued their Q1 2024 earnings per share estimates for shares of Chemed in a research note issued to investors on Thursday, January 19th. Oppenheimer analyst M. Wiederhorn expects that the company will post earnings per share of $5.26 for the quarter. The consensus estimate for Chemed’s current full-year earnings is $18.69 per share. Oppenheimer also issued estimates for Chemed’s Q2 2024 earnings at $5.67 EPS, Q3 2024 earnings at $5.62 EPS and FY2025 earnings at $24.42 EPS.

CHE has been the subject of a number of other research reports. Royal Bank of Canada increased their price target on Chemed from $541.00 to $545.00 and gave the company an “outperform” rating in a research report on Thursday, November 3rd. StockNews.com downgraded Chemed from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, November 9th.

Chemed Stock Down 0.4 %

Shares of Chemed stock opened at $497.86 on Friday. Chemed has a 1-year low of $430.16 and a 1-year high of $528.72. The company has a debt-to-equity ratio of 0.13, a current ratio of 0.67 and a quick ratio of 0.63. The business’s fifty day moving average price is $507.73 and its two-hundred day moving average price is $485.76. The company has a market capitalization of $7.40 billion, a P/E ratio of 28.93, a PEG ratio of 3.52 and a beta of 0.55.

Chemed (NYSE:CHEGet Rating) last issued its quarterly earnings data on Monday, October 31st. The company reported $4.74 earnings per share for the quarter, beating analysts’ consensus estimates of $4.61 by $0.13. Chemed had a return on equity of 44.29% and a net margin of 12.31%. The firm had revenue of $526.47 million during the quarter, compared to analyst estimates of $527.05 million. During the same quarter last year, the firm earned $5.06 EPS. Chemed’s quarterly revenue was down 2.3% on a year-over-year basis.

Institutional Investors Weigh In On Chemed

Several institutional investors and hedge funds have recently added to or reduced their stakes in CHE. Dark Forest Capital Management LP bought a new position in Chemed during the 2nd quarter worth $34,000. IFP Advisors Inc grew its stake in shares of Chemed by 13.7% in the 3rd quarter. IFP Advisors Inc now owns 274 shares of the company’s stock valued at $37,000 after buying an additional 33 shares during the period. Canada Pension Plan Investment Board acquired a new stake in shares of Chemed in the 1st quarter valued at about $46,000. Quadrant Capital Group LLC grew its stake in shares of Chemed by 29.2% in the 3rd quarter. Quadrant Capital Group LLC now owns 115 shares of the company’s stock valued at $50,000 after buying an additional 26 shares during the period. Finally, Wipfli Financial Advisors LLC acquired a new stake in shares of Chemed in the 3rd quarter valued at about $54,000. 91.12% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Chemed

In other news, CEO Kevin J. Mcnamara sold 2,000 shares of Chemed stock in a transaction on Monday, November 21st. The stock was sold at an average price of $505.76, for a total value of $1,011,520.00. Following the completion of the sale, the chief executive officer now directly owns 121,264 shares of the company’s stock, valued at approximately $61,330,480.64. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other news, CEO Kevin J. Mcnamara sold 2,000 shares of the business’s stock in a transaction dated Monday, November 21st. The stock was sold at an average price of $505.76, for a total value of $1,011,520.00. Following the sale, the chief executive officer now directly owns 121,264 shares in the company, valued at $61,330,480.64. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, VP Michael D. Witzeman sold 1,300 shares of the company’s stock in a transaction dated Thursday, November 3rd. The stock was sold at an average price of $482.62, for a total value of $627,406.00. Following the sale, the vice president now owns 1,186 shares in the company, valued at approximately $572,387.32. The disclosure for this sale can be found here. Insiders sold a total of 9,036 shares of company stock valued at $4,444,780 in the last quarter. Corporate insiders own 4.03% of the company’s stock.

Chemed Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, December 5th. Shareholders of record on Monday, November 14th were issued a $0.38 dividend. The ex-dividend date was Thursday, November 10th. This represents a $1.52 annualized dividend and a yield of 0.31%. Chemed’s dividend payout ratio (DPR) is 8.83%.

About Chemed

(Get Rating)

Chemed Corp. engages in the provision of healthcare and maintenance services. It operates through the VITAS and Roto-Rooter segments. The VITAS segment offers hospice and palliative care services to patients through a network of physicians, registered nurses, home health aides, social workers, clergy, and volunteers.

See Also

Earnings History and Estimates for Chemed (NYSE:CHE)

Receive News & Ratings for Chemed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed and related companies with MarketBeat.com's FREE daily email newsletter.